1. Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline

   • Nina Tamirisa
   • Kelly K. Hunt

   ASO Perspectives 06 January 2022 Pages: 1489 - 1492

2. Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: PRODIGE 23 Trial

   • Martin R. Weiser

   ASO Perspectives 26 November 2021 Pages: 1493 - 1495

3. Too Many or Too Few? How Many Lymph Nodes Are Enough?

   • Teviah E. Sachs

   Pancreatic Tumors 22 October 2021 Pages: 1496 - 1497

4. Biomarker-Driven Prognostication in Merkel Cell Carcinoma: A Paradigm for Personalized Therapy

   • Beth A. Helmink
   • George Ansstas
   • Ryan C. Fields

   Melanoma 17 November 2021 Pages: 1498 - 1501

5. Editorial: Impact of the Covid-19 Pandemic on Breast Cancer Treatment and Patient Experience

   • Jill R. Dietz

   Breast Oncology 02 January 2022 Pages: 1502 - 1503

6. Communication is the Key to an Improved Patient Experience When it Comes to Surgical Delays

   • Jill R. Dietz

   Breast Oncology 02 January 2022 Pages: 1504 - 1505

7. Removing Barriers to Access Starts with a Phone Call: Impact of Pre-Visit Coordination of Care in Efficiency of Therapy and Patient and Provider Satisfaction

   • Andrew J. Sinnamon
   • Pamela J. Hodul
   • Jose M. Pimiento

   Gastrointestinal Oncology 01 December 2021 Pages: 1506 - 1508

8. The Importance of Clinical Decision-Making in Surgical Planning for Non-Small Cell Lung Cancer

   • Hollis Johanson
   • Ikenna Okereke

   Thoracic Oncology 08 November 2021 Pages: 1509 - 1510

9. Chest CT-Derived Muscle Metrics for Sarcopenia: Choosing the Right Target

   • Palmi Shah
   • Mark Supanich

   Thoracic Oncology 13 November 2021 Pages: 1511 - 1512

10. The Paradox of Early Stage Rectal Cancer: More ReSeARCh in the Right Direction

    • Paolo Goffredo
    • J. Joshua Smith

    Colorectal Cancer 30 November 2021 Pages: 1513 - 1515

11. Cost-Effectiveness of Watch and Wait: What is in the Box of this Organ-Preservation Strategy?

    • Rodrigo Oliva Perez

    Colorectal Cancer 08 January 2022 Pages: 1516 - 1517

12. Access to Colorectal Cancer Care for Medicaid-Insured Patients at Designated Cancer Facilities

    • Victoria A. Marks
    • Walter R. Hsiang
    • Kevin M. Schuster

    ASO Research Letter 11 November 2021 Pages: 1518 - 1522

13. Association of Liberal Fluid Therapy for Colorectal Cancer Surgery and Long-Term Oncologic Recurrence

    • Andres Zorrilla-Vaca
    • Javier Ripolles-Melchor
    • Alicia Ruiz-Escobar

    ASO Research Letter 08 November 2021 Pages: 1523 - 1525

    

14. Is Axillary Radiation not Inferior to Axillary Dissection for Sentinel Lymph Node-Positive Breast Cancer After Neoadjuvant Chemotherapy?

    • Tahsin M. Khan
    • Alexander J. Rossi
    • Judy C. Boughey

    ASO Research Letter 20 October 2021 Pages: 1526 - 1527

    

15. Surgical Excision Versus Neoadjuvant Radiotherapy Followed by Delayed Surgical Excision of Ductal Carcinoma In Situ (NORDIS)

    • Alexander J. Rossi
    • Emily A. Verbus
    • Irene L. Wapnir

    ASO Research Letter 02 September 2021 Pages: 1528 - 1529

    

16. Preoperative Use of a Radiation Boost to Enhance Effectiveness of Immune Checkpoint Blockade Therapy in Operable Breast Cancer

    • Emily A. Verbus
    • Alexander J. Rossi
    • Julia C. Tchou

    ASO Research Letter 16 November 2021 Pages: 1530 - 1532

    

17. A Novel Criterion for Lymph Nodes Dissection in Distal Pancreatectomy for Ductal Adenocarcinoma: A Population Study of the US SEER Database

    • Weishen Wang
    • Ziyun Shen
    • Baiyong Shen

    Pancreatic Tumors 07 October 2021 Pages: 1533 - 1539

    

18. ASO Author Reflections: Lymphadenectomy in Distal Pancreatectomy for Ductal Adenocarcinoma: How to Do Better?

    • Weishen Wang
    • Baiyong Shen

    ASO Author Reflections 29 September 2021 Pages: 1540 - 1541

19. Landmark Series: Importance of Pancreatic Resection Margins

    • Mihir M. Shah
    • Jashodeep Datta
    • David A. Kooby

    Pancreatic Tumors 05 January 2022 Pages: 1542 - 1550

    

20. ASO Author Reflections: Pancreatic Resection Margins—Chasing Moons

    • Mihir M. Shah
    • Jashodeep Datta
    • David A. Kooby

    ASO Author Reflections 07 January 2022 Pages: 1551 - 1552

21. Sarcopenia as a Predictor of Survival in Patients with Pancreatic Adenocarcinoma After Pancreatectomy

    • Hadass Rom
    • Shlomit Tamir
    • Eran Sadot

    Pancreatic Tumors 30 October 2021 Pages: 1553 - 1563

    

22. ASO Visual Abstract: Sarcopenia as a Predictor of Survival in Patients with Pancreatic Adenocarcinoma After Pancreatectomy

    • Hadass Rom
    • Shlomit Tamir
    • Eran Sadot

    ASO Visual Abstract 08 January 2022 Pages: 1564 - 1565

23. Determining Hospital Volume Threshold for Safety of Minimally Invasive Pancreaticoduodenectomy: A Contemporary Cutpoint Analysis

    • Patricia C. Conroy
    • Lucia Calthorpe
    • Mohamed A. Adam

    Pancreatic Tumors 01 November 2021 Pages: 1566 - 1574

    

24. ASO Author Reflections: An Objective Hospital Volume Threshold for Minimally Invasive Pancreaticoduodenectomy

    • Patricia C. Conroy
    • Adnan Alseidi
    • Mohamed A. Adam

    ASO Author Reflections 12 November 2021 Pages: 1575 - 1576

25. ASO Visual Abstract: Determining Hospital Volume Threshold for the Safety of Minimally Invasive Pancreaticoduodenectomy: A Contemporary Cutpoint Analysis

    • Patricia C. Conroy
    • Lucia Calthorpe
    • Mohamed A. Adam

    ASO Visual Abstract 15 January 2022 Pages: 1577 - 1578

26. Neoadjuvant Chemotherapy Switch in Borderline Resectable/Locally Advanced Pancreatic Cancer

    • Roberto Alva-Ruiz
    • Lavanya Yohanathan
    • Mark J. Truty

    Pancreatic Tumors Open access 01 November 2021 Pages: 1579 - 1591

    

27. ASO Author Reflections: Neoadjuvant Chemotherapy Switch: Optimizing Neoadjuvant Treatment Sequencing in Pancreas Cancer

    • Roberto Alva-Ruiz
    • Mark J. Truty

    ASO Author Reflections Open access 27 October 2021 Pages: 1592 - 1593

28. ASO Visual Abstract: Neoadjuvant Chemotherapy Switch in Borderline Resectable/Locally Advanced Pancreatic Cancer

    • Roberto Alva-Ruiz
    • Lavanya Yohanathan
    • Mark J. Truty

    ASO Visual Abstract 22 November 2021 Pages: 1594 - 1595

29. Circulating Tumor DNA as a Potential Prognostic Marker in Patients with Borderline-Resectable Pancreatic Cancer Undergoing Neoadjuvant Chemotherapy Followed by Pancreatectomy

    • Yuji Kitahata
    • Manabu Kawai
    • Hiroki Yamaue

    Pancreatic Tumors 01 November 2021 Pages: 1596 - 1605

    

30. ASO Visual Abstract: Circulating Tumor DNA as a Potential Prognostic Marker in Patients with Borderline-Resectable Pancreatic Cancer Undergoing Neoadjuvant Chemotherapy Followed by Pancreatectomy

    • Yuji Kitahata
    • Manabu Kawai
    • Hiroki Yamaue

    ASO Visual Abstract 08 November 2021 Pages: 1606 - 1607

31. Distinct Survival Outcomes in Subgroups of Stage III Pancreatic Cancer Patients: Taiwan Cancer Registry and Surveillance, Epidemiology and End Results registry

    • Tzu-Pin Lu
    • Chien-Hui Wu
    • Yu-Wen Tien

    Pancreatic Tumors Open access 13 November 2021 Pages: 1608 - 1615

    

32. ASO Author Reflections: Identification of Prognostic Factors for Stage-III Pancreatic Ductal Adenocarcinoma patients.

    • Amrita Chattopadhyay
    • Chien-Hui Wu
    • Tzu-Pin Lu

    ASO Author Reflections 20 November 2021 Pages: 1616 - 1617

33. ASO Visual Abstract: Distinct Survival Outcomes for Subgroups of Stage 3 Pancreatic Cancer Patients: Taiwan Cancer Registry and Surveillance, Epidemiology, and End Results Registry

    • Tzu-Pin Lu
    • Chien-Hui Wu
    • Yu-Wen Tien

    ASO Visual Abstract 12 January 2022 Pages: 1618 - 1619

34. Merkel Cell Polyomavirus Antibody Titer Predicts Recurrence-Free Survival

    • Aaron J. Arroyave
    • James M. Lewis
    • Laura M. Enomoto

    Melanoma 01 December 2021 Pages: 1620 - 1626

    

35. ASO Author Reflections: The Evolving and Expanding Role of Merkel Cell Polyomavirus Antibody Titers

    • Aaron J. Arroyave
    • Laura M. Enomoto

    ASO Author Reflections 06 January 2022 Pages: 1627 - 1628

36. COVID-19 is Affecting the Presentation and Treatment of Melanoma Patients in the Northeastern United States

    • Catherine H. Davis
    • Jason Ho
    • Adam C. Berger

    Melanoma 19 November 2021 Pages: 1629 - 1635

    

37. ASO Visual Abstract: COVID-19 is Affecting the Presentation and Treatment of Melanoma Patients in the Northeastern United States

    • Catherine H. Davis
    • Jason Ho
    • Adam C. Berger

    ASO Visual Abstract 01 January 2022 Pages: 1636 - 1636

38. External Validation of a Dutch Predictive Nomogram for Complete Response to T-VEC in an Independent American Patient Cohort

    • Emma H. A. Stahlie
    • Michael J. Carr
    • Alexander C. J. van Akkooi

    Melanoma 23 November 2021 Pages: 1637 - 1644

    

39. ASO Author Reflections: Validation of Prediction Model for Response to Treatment with T-VEC

    • Emma H. A. Stahlie
    • Alexander C. J. van Akkooi

    ASO Author Reflections 09 January 2022 Pages: 1645 - 1646

40. ASO Visual Abstract: External Validation of a Dutch Predictive Nomogram for Complete Response to T-VEC in an Independent American Patient Cohort

    • Emma H. A. Stahlie
    • Michael J. Carr
    • Alexander C. J. van Akkooi

    ASO Visual Abstract 08 January 2022 Pages: 1647 - 1648

41. Patient Perceptions of Changes in Breast Cancer Care and Well-Being During COVID-19: A Mixed Methods Study

    • Abigail Ludwigson
    • Victoria Huynh
    • Sarah Tevis

    Breast Oncology 20 December 2021 Pages: 1649 - 1657

    

42. ASO Visual Abstract: Patient Perceptions of Changes in Breast Cancer Care and Well-Being During COVID-19: A Mixed-Methods Study

    • Abigail Ludwigson
    • Victoria Huynh
    • Sarah Tevis

    ASO Visual Abstract 16 January 2022 Pages: 1658 - 1659

43. Atypical Lobular Hyperplasia and Classic Lobular Carcinoma In Situ Can Be Safely Managed Without Surgical Excision

    • Alison Laws
    • Fisher Katlin
    • Tari A. King

    Breast Oncology 23 September 2021 Pages: 1660 - 1667

    

44. ASO Visual Abstract: Atypical Lobular Hyperplasia and Classic Lobular Carcinoma In Situ Can Be Safely Managed Without Surgical Excision

    • Alison Laws
    • Fisher Katlin
    • Tari A. King

    ASO Visual Abstract 03 November 2021 Pages: 1668 - 1669

45. Comparison of Outcomes for Classic-Type Lobular Carcinoma In Situ Managed with Surgical Excision After Core Biopsy Versus Observation

    • Regina Matar
    • Varadan Sevilimedu
    • Melissa Pilewskie

    Breast Oncology 20 October 2021 Pages: 1670 - 1679

    

46. ASO Author Reflections: Observation After a Core Biopsy Diagnosis of Classic-Type LCIS Is a Safe Standard of Practice

    • Regina Matar
    • Melissa Pilewskie

    ASO Author Reflections 23 October 2021 Pages: 1680 - 1681

47. ASO Visual Abstract: Comparison of Outcomes for Classic-Type Lobular Carcinoma In Situ Managed with Surgical Excision After Core Biopsy Versus Observation

    • Regina Matar
    • Varadan Sevilimedu
    • Melissa Pilewskie

    ASO Visual Abstract 08 January 2022 Pages: 1682 - 1682

48. Neoadjuvant Endocrine Therapy and Delays in Surgery for Ductal Carcinoma in Situ: Implications for the Coronavirus Pandemic

    • Austin D. Williams
    • Cecilia Chang
    • Richard J. Bleicher

    Breast Oncology 11 October 2021 Pages: 1683 - 1691

    

49. ASO Author Reflections: Neoadjuvant Endocrine Therapy: A Pill in Time Saves Nine

    • Austin D. Williams
    • Richard J. Bleicher

    ASO Author Reflections 06 January 2022 Pages: 1692 - 1693

50. ASO Visual Abstract: Neoadjuvant Endocrine Therapy and Delays in Surgery for Ductal Carcinoma in Situ: Implications for the Coronavirus Pandemic

    • Austin D. Williams
    • Cecilia Chang
    • Richard J. Bleicher

    ASO Visual Abstract 26 October 2021 Pages: 1694 - 1694